Rhodojaponin VI
Based on 1 Customer Validation
Rhodojaponin VI is an orally active diterpenoid compound found in hododendron molle G. Don
(Ericaceae) (RM). Rhodojaponin VI binds rat N-Ethylmaleimide-sensitive fusion (NSF) with a Kd of 1.03 μM. Rhodojaponin VI blocks the MDM2-Notch1 signalling pathway by reducing MDM2 and Notch1 expression. Rhodojaponin VI indirectly reduces Cav2.2 current intensity by inhibiting NSF-mediated Cav2.2 trafficking. Rhodojaponin VI alleviates glomerulonephritis progression and podocyte injury in passive heymann nephritis rats. Rhodojaponin VI also has antinociceptive effects. Rhodojaponin VI can be used for the researches of heymann nephritis and pain.
For research use only. We do not sell to patients.
- Purity: 99.78%
- CAS No.: 37720-87-9
- Formula: C20H34O7
- Molecular Weight:386.48
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All Calcium Channel Isoforms
More
Biological Activity
(Ericaceae) (RM). Rhodojaponin VI binds rat N-Ethylmaleimide-sensitive fusion (NSF) with a Kd of 1.03 μM. Rhodojaponin VI blocks the MDM2-Notch1 signalling pathway by reducing MDM2 and Notch1 expression. Rhodojaponin VI indirectly reduces Cav2.2 current intensity by inhibiting NSF-mediated Cav2.2 trafficking. Rhodojaponin VI alleviates glomerulonephritis progression and podocyte injury in passive heymann nephritis rats. Rhodojaponin VI also has antinociceptive effects. Rhodojaponin VI can be used for the researches of heymann nephritis and pain[1][2][3].
Rhodojaponin VI ( pre-treated) partially blocks the MDM2-Notch1 signalling pathway in C5b-9-induced human podocyte cells by reducing C5b-9-induced MDM2 and Notch1 expression without altering p53 or Numb levels[1].
Rhodojaponin VI (0.01-100 μM; 20 min) enhances the thermal stability of NSF in rat DRG neuron lysates[2].
Rhodojaponin VI binds NSF directly (Kd = 1.03 ± 0.65 μM)[2].
Rhodojaponin VI (30 μM; 2-30 min) does not change Cav2.2 current intensity extracellularly but decreases it intracellularly in Cav2.2-HEK cells[2].
Rhodojaponin VI (30 μM; overnight) reverses the NSF-mediated increase in surface Cav2.2 expression and Cav2.2 current density in Cav2.2-HEK cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Cav2.2-HEK cells
-
Concentration:30 μM
-
Incubation Time:overnight
-
Result:Reversed the increase in surface Cav2.2 expression induced by NSF overexpression.
Rhodojaponin VI (0.001-0.05 mg/kg; i.p.; single dose) alleviates neuropathic pain in chronic constriction injury rats models[2].
Rhodojaponin VI (0.04-0.2 mg/kg, i.p.) exhibits potent antinociceptive effects in HOAC-induced writhing test in mice (with a writhe inhibition rate of 88.7%)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rats (male, 150–180 g, induced passive Heymann nephritis)[1]
-
Dosage:0.02 mg/kg
-
Administration:p.o.; daily; 4 weeks (starting 1 day before passive Heymann nephritis induction)
-
Result:Reduced peak proteinuria and increased serum albumin levels.
Reversed decreased body weight, reduced serum triglyceride levels.
Attenuated glomerular IgG immune complex deposition.
Reduced foot process fusion and restored nephrin and WT-1 expression.
Decreased desmin expression, and decreased renal MDM2 and Notch1 protein expression without altering p53 or Numb levels.
-
Animal Model:Sprague-Dawley rats (adult female, chronic constriction injury model)[2]
-
Dosage:0.001, 0.005, 0.01, 0.05 mg/kg
-
Administration:i.p.; single dose
-
Result:Significantly increased paw withdrawal threshold and thermal withdrawal latency.
Almost eliminated the C-component of CAPs within 30 seconds, with partial recovery after washing.
Had no effect on A-components of CAPs was observed.
Chemical Information
-
CAS No. 37720-87-9
-
Appearance Solid
-
Molecular Weight 386.48
-
Formula C20H34O7
-
Color White to off-white
-
SMILES
OC1[C@@]23[C@](CC[C@@]1([H])[C@](O)(C3)C)([H])[C@@](O)([C@@]4([H])[C@]([C@@H](C2)O)(C(C)([C@H]([C@@H]4O)O)C)O)C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 100 mg/mL (258.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Song A, et al. Rhodojaponin VI ameliorates podocyte injury related with MDM2/Notch1 pathway in rat experimental membranous nephropathy. Nephrology (Carlton). 2024;29(9):555-564. [Content Brief]
[2]. Chen K, et al. Rhodojaponin VI indirectly targets Cav2.2 channels via N-ethylmaleimide-sensitive fusion protein to alleviate neuropathic pain. Acta Pharm Sin B. 2023;13(3):1326-1336. [Content Brief]
[3]. Zheng G, et al. Antinociceptive Grayanane Diterpenoids from the Leaves of Pieris japonica. J Nat Prod. 2019 Dec 27;82(12):3330-3339. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5875 mL | 12.9373 mL | 25.8746 mL | 64.6864 mL |
| 5 mM | 0.5175 mL | 2.5875 mL | 5.1749 mL | 12.9373 mL | |
| 10 mM | 0.2587 mL | 1.2937 mL | 2.5875 mL | 6.4686 mL | |
| 15 mM | 0.1725 mL | 0.8625 mL | 1.7250 mL | 4.3124 mL | |
| 20 mM | 0.1294 mL | 0.6469 mL | 1.2937 mL | 3.2343 mL | |
| 25 mM | 0.1035 mL | 0.5175 mL | 1.0350 mL | 2.5875 mL | |
| 30 mM | 0.0862 mL | 0.4312 mL | 0.8625 mL | 2.1562 mL | |
| 40 mM | 0.0647 mL | 0.3234 mL | 0.6469 mL | 1.6172 mL | |
| 50 mM | 0.0517 mL | 0.2587 mL | 0.5175 mL | 1.2937 mL | |
| 60 mM | 0.0431 mL | 0.2156 mL | 0.4312 mL | 1.0781 mL | |
| 80 mM | 0.0323 mL | 0.1617 mL | 0.3234 mL | 0.8086 mL | |
| 100 mM | 0.0259 mL | 0.1294 mL | 0.2587 mL | 0.6469 mL |
Rhodojaponin VI Related Classifications
HY-N12768 Related Classifications
Powered by Bioz